180 Life Sciences (ATNF)

Executive Summary

180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammation, fibrosis, and pain. Its sole pipeline candidate is a Phase 2/3 trial of adalimumab injection for frozen shoulder, which completed in June 2023. The company also operates a financial technology platform for securitization and trading of real-world assets as digital securities, a unique dual-focus model. With a market capitalization of approximately $21.6 million, 180 Life Sciences faces significant risk due to its narrow pipeline and reliance on a single late-stage trial. The frozen shoulder trial results, if positive, could be a major value driver, but no data has been publicly released. The company's ability to advance its drug development and generate revenue from its digital securities platform remains uncertain. Given the lack of approved products and the speculative nature of its pipeline, 180 Life Sciences is a high-risk investment.

Upcoming Catalysts (preview)

• Q3 2026Publication of Phase 2/3 Frozen Shoulder Trial Results40% success
• TBDAnnouncement of Next Pipeline Candidate or Trial Initiation20% success
• TBDProgress on Digital Securities Platform (e.g., partnership or license)15% success